Nathan P Coussens
Overview
Explore the profile of Nathan P Coussens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dexheimer T, Davoudi Z, Coussens N, Silvers T, Morris J, Takebe N, et al.
SLAS Discov
. 2025 Feb;
32:100222.
PMID: 39999911
Dysregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is a key contributor to cancer, making PI3K inhibitors a promising approach for targeted therapy. The selectivity of available inhibitors varies across different...
2.
Dexheimer T, Coussens N, Silvers T, Jones E, Chen L, Fang J, et al.
SLAS Discov
. 2024 Oct;
29(7):100186.
PMID: 39362362
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that regulates genes of drug transporters and metabolic enzymes to detoxify small molecule xenobiotics. It has a complex role in...
3.
Crystal structure and mechanistic studies of the PPM1D serine/threonine phosphatase catalytic domain
Kumar J, Kosek D, Durell S, Miller Jenkins L, Debnath S, Coussens N, et al.
J Biol Chem
. 2024 Jul;
300(8):107561.
PMID: 39002674
Protein phosphatase 1D (PPM1D, Wip1) is induced by the tumor suppressor p53 during DNA damage response signaling and acts as an oncoprotein in several human cancers. Although PPM1D is a...
4.
Kunkel M, Coussens N, Morris J, Taylor R, Dexheimer T, Jones E, et al.
Cancer Res
. 2024 Jun;
84(15):2403-2416.
PMID: 38861359
The NCI60 human tumor cell line screen has been in operation as a service to the cancer research community for more than 30 years. The screen operated with 96-well plates,...
5.
Crawford M, Tripu D, Barritt S, Jing Y, Gallimore D, Kales S, et al.
ACS Chem Biol
. 2023 Sep;
18(10):2249-2258.
PMID: 37737090
The human acetyltransferase paralogues EP300 and CREBBP are master regulators of lysine acetylation whose activity has been implicated in various cancers. In the half-decade since the first drug-like inhibitors of...
6.
Dexheimer T, Coussens N, Silvers T, Wright J, Morris J, Doroshow J, et al.
Cancer Res Commun
. 2023 Aug;
3(8):1648-1661.
PMID: 37637936
Significance: Clinical efficacy of DNA-damaging anticancer drugs can be influenced by the DNA damage response in tumor cells. The potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways...
7.
Morris J, Kunkel M, White S, Wishka D, Lopez O, Bowles L, et al.
Mol Cancer Ther
. 2023 Aug;
22(11):1270-1279.
PMID: 37550087
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell...
8.
Crawford M, Tripu D, Barritt S, Jing Y, Gallimore D, Kales S, et al.
bioRxiv
. 2023 Jun;
PMID: 37292747
The human acetyltransferase paralogs EP300 and CREBBP are master regulators of lysine acetylation whose activity has been implicated in various cancers. In the half-decade since the first drug-like inhibitors of...
9.
Baljinnyam B, Coussens N, Simeonov A
Front Cell Dev Biol
. 2023 Mar;
11:1163966.
PMID: 36910140
No abstract available.
10.
Clausse V, Fang Y, Tao D, Tagad H, Sun H, Wang Y, et al.
ACS Pharmacol Transl Sci
. 2022 Oct;
5(10):993-1006.
PMID: 36268125
Wild-type P53-induced phosphatase 1 (WIP1), also known as or PP2Cδ, is a serine/threonine protein phosphatase induced by P53 after genotoxic stress. WIP1 inhibition has been proposed as a therapeutic strategy...